C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 401/14 (2006.01) A61K 47/48 (2006.01) A61K 49/22 (2006.01) A61K 51/04 (2006.01) C07D 401/12 (2006.01) C07F 9/6558 (2006.01) C07K 14/705 (2006.01)
Patent
CA 2727746
The present invention describes novel compounds of formula: (Q)d-L n-C h, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, and optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, and X-ay contrast agent, or an ultrasound contrast agent.
Harris Thomas David
Rajopadhye Miland
Bristol-Myers Squibb Pharma Company
Dimock Stratton Llp
Lantheus Medical Imaging Inc.
LandOfFree
Quinolone vitronectin receptor antagonist pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinolone vitronectin receptor antagonist pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinolone vitronectin receptor antagonist pharmaceuticals will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1867377